Roche plans to call its new breast cancer pill Wilserdly and has registered the name in several jurisdictions ahead of possible approval of a drug it hopes will become a dominant new treatment for the disease. BBG.
Roche plans to call its new breast cancer pill Wilserdly and has registered the name in several jurisdictions ahead of possible approval of a drug it hopes will become a dominant new treatment for the disease. BBG.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in